SCHEMBL23419287

SCHEMBL23419287

COC(=O)Nc1ccc(-c2ccc(OC)cc2Cl)n2cc(Cc3nc4cc(Cl)ccc4[nH]3)nc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MARS2 Q96GW9 4/20 0.40
▸ FPR2 P25090 2/20 0.35
▸ PRMT5 O14744 2/20 0.35
▸ WDR77 Q9BQA1 2/20 0.35
▸ NTRK1 P04629 2/20 0.35
▸ NTRK2 Q16620 2/20 0.35
▸ AGPAT2 O15120 3/20 0.35
▸ ALDH1A1 P00352 5/20 0.34
▸ MAPT P10636 3/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ LMNA P02545 4/20 0.34
▸ TP53 P04637 1/20 0.34
▸ FLT3 P36888 1/20 0.33
▸ MEN1 O00255 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ GAA P10253 1/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ TDP1 Q9NUW8 2/20 0.33
▸ POLB P06746 2/20 0.33
▸ PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23419554 0.94 MARS2 (0.38) MARS2FPR2PRMT5WDR77NTRK1
SCHEMBL20595970 0.94 MEN1 (0.39) MARS2FPR2PRMT5WDR77NTRK1
SCHEMBL23419396 0.91 NTRK1 (0.37) MARS2FPR2PRMT5WDR77NTRK1
SCHEMBL20595848 0.88 MEN1 (0.39) MARS2FPR2PRMT5WDR77NTRK1
SCHEMBL20595586 0.85 ABL1 (0.41) MARS2FPR2PRMT5WDR77NTRK1
SCHEMBL30145089 0.85 ABL1 (0.41) MARS2FPR2PRMT5WDR77NTRK1
SCHEMBL23419532 0.85 MARS2 (0.41) MARS2
SCHEMBL20595877 0.83 MARS2 (0.52) MARS2FPR2PRMT5WDR77ALDH1A1
SCHEMBL20595745 0.80 MARS2 (0.54) MARS2FPR2PRMT5WDR77ALDH1A1
SCHEMBL20595816 0.80 MARS2 (0.43) MARS2FPR2PRMT5WDR77ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 MARS2 12/4885FPR2 4177/4885PRMT5 379/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR MARS2 5/4885FPR2 4042/4885PRMT5 285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback